The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > Incretin-based therapies and SGLT2 inhibitors in DIO mouse model

Differentiate your incretin-based therapies and SGLT2 inhibitors in DIO mice: clues for positioning

Differentiate your drug against competitors beyond anti-diabetic effects with validated in vivo experiments

key objectives

  • In vivo validation of the main classes of approved anti-diabetic compounds
  • Differentiate your drug against competitors through in vivo experiments to unmask specific benefits/scientific advantages
  • Take advantage of Physiogenex’s unique state of the art technical and scientific expertise

pharmacological validation

  • GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors